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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second cancer-
related cause of death by 2030. Identifying novel risk factors, including genetic risk loci,
could be instrumental in risk stratification and implementation of prevention strategies.
Long noncoding RNAs (lncRNAs) are involved in regulation of key biological processes,
and the possible role of their genetic variability has been unexplored so far. Combining
genome wide association studies and functional data, we investigated the genetic vari-
ability in all lncRNAs. We analyzed 9893 PDAC cases and 9969 controls and identified
a genome-wide significant association between the rs7046076 SNP and risk of devel-
oping PDAC (P = 9.73 × 10−9). This SNP is located in the NONHSAG053086.2 (lnc-
SMC2-1) gene and the risk allele is predicted to disrupt the binding of the lncRNA with
the micro-RNA (miRNA) hsa-mir-1256 that regulates several genes involved in cell
cycle, such as CDKN2B. The CDKN2B region is pleiotropic and its genetic variants have
been associated with several human diseases, possibly though an imperfect interaction
between lncRNA and miRNA. We present a novel PDAC risk locus, supported by a
genome-wide statistical significance and a plausible biological mechanism.
K E YWORD S
association study, long noncoding RNA, pancreatic cancer, single nucleotide polymorphism
1 | INTRODUCTION
Pancreatic cancer and particularly pancreatic ductal adenocarcinoma
(PDAC) is the fifth cause of cancer-related death in the western
world,1 and it is projected to become the second by 2030.2 The inci-
dence is almost equal to the mortality, with a survival around 10% at
5 years after diagnosis.3 One of the reasons for this meager prognosis
is the absence of specific symptoms, making early detection and diag-
nosis a hard challenge.4 Additionally, surgery remains the only curative
treatment, but only a minority of the patients can receive it, because
most are diagnosed at advanced stage.5 A possible strategy to reduce
the burden of this disease would be to find biological risk markers that
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enable a timely diagnosis, and/or the stratification of the population
according to the risk in order to plan preventive strategies. Several
epidemiologic PDAC risk factors have been identified, including ciga-
rette smoking, heavy alcohol intake, type two diabetes mellitus and
chronic pancreatitis.6,7 In addition, several studies have identified
body mass index as a causative factor for PDAC development using a
Mendelian randomization approach.8-10 The genetic susceptibility to
PDAC is the result of the involvement of rare high penetrance muta-
tions and high frequency low penetrance variants discovered through
genome wide association studies (GWAS) or large multicentric candi-
date gene approaches.11-22
The recent advances in the knowledge on the regulatory regions of
the human genome have highlighted that several GWAS hits associated
with a variety of human traits, including PDAC risk, are located in DNA
sequences containing noncoding RNA (ncRNA).23 The vast majority of
ncRNAs consists of long noncoding RNA (lncRNA), and recent evi-
dences suggest that around 68% of the human transcriptome consists
of lncRNAs.24 lncRNAs are generally defined as RNA transcripts longer
than 200 nucleotides with no protein-coding potential.25 Although
lncRNAs cannot encode any functional protein, they are involved in
diverse biological processes, playing essential roles in maintaining cell
growth, differentiation and proliferation.26,27 There is an increasing
amount of evidence suggesting their role in cancer development, pro-
gression and metastatic spread.27 The involvement of lncRNAs in can-
cer could be the results of a plethora of mechanisms such as the
regulation of gene expression (epigenetic, transcriptional and post-tran-
scriptional) through the interaction with other regulatory molecules,
such as micro-RNAs (miRNAs), and through the direct binding to protein
complexes such as transcription factors. All these mechanisms have
been reviewed by Slack and Chinnaiyan.27
LncRNAs are highly polymorphic and single nucleotide polymor-
phisms (SNPs) localized in their sequence (lncSNPs) could influence
their expression and therefore have an impact on their function as
master regulators.28 At least two PDAC risk loci, identified through
GWAS, have been reported to be in lncRNAs (LINC00673-
rs11655237, LINC-PINT-rs6971499), and examples also exist in other
cancer types such as colorectal,29 glioma,30 lung,31 hepatocellular car-
cinoma32 and ovarian cancer.33
Despite these evidences, a systematic search of the effect of
lncSNPs in the development of PDAC has never been attempted.
With the aim of finding new susceptibility loci, we have scanned the
entire human genome for SNPs in lncRNAs and analyzed their possi-
ble involvement in PDAC susceptibility by using a two-step study on
9893 cases and 9969 controls.
2 | MATERIALS AND METHODS
2.1 | Study populations
For the discovery phase data from the published GWAS PanScan I,
PanScan II and PanC4 were downloaded from the database of Geno-
types and Phenotypes (dbGaP) website (study accession numbers:
phs000206.v5.p3 and phs000648.v1.p1, project reference: #12644).
All the individuals were genotyped using either Illumina Infinium
HumanHap550v3 (PanScan I), Illumina Infinium Human610-Quad
(PanScan II) or HumanOmniExpressExome-8v1 (PanC4) DNA Analysis
Genotyping BeadChip. Each participating study (within PanScan I,
PanScan II and PanC4) obtained informed consent from study partici-
pants, and approval from the responsible institutional review board, as
described in the original papers.34-37 After downloading the geno-
types, we performed imputation and quality controls. Briefly, the
genotypes were phased using SHAPEIT v2 software. The three GWAS
data sets were imputed separately using IMPUTE4 with 1000
Genomes-phase 3 as the reference panel. Prior to imputation, quality
control (QC) filters included: removal of individuals with gender mis-
matches, call rate < 0.98, minimal or excessive heterozygosity (>3 SDs
from the mean) or cryptic relatedness (PI_HAT > 0.2). SNPs with
minor allele frequency (MAF) < 0.01, call rate < 0.98 or evidence for
violations of Hardy-Weinberg Equilibrium (P < 1 × 10−6) were
excluded. Postimputation SNPs with low imputation quality (INFO
score r2 < 0.7), MAF < 0.01 or call rate < 0.98 were excluded. Princi-
pal component analysis (PCA) was carried out with PLINK 2.0 (www.
cog-genomics.org/plink/2.0/) including genotypes from all the
populations of the phase 3 of the 1000 Genomes Project. Individuals
not clustering in the PCA with the 1000 Genomes subjects of
European descent were excluded from further analysis. For this phase,
genotyping data of 14 269 individuals (7207 cases and 7062 controls)
were used. The final data set had genotypes for 7 509 345 SNPs.
Additional information regarding SNP filtering for each data set is
shown in Table S1. The “inflation factor” did not showed evidence of
systematic inflation (λ = 1.000 for PanScan I, λ = 1.015 for PanScan II,
λ = 1.000 for PanC4, and λ = 1.000 for the aggregate data set). For
the replication phase, the genotyping was conducted in 5593 individ-
uals (2686 PDAC patients and 2907 controls) belonging to the PAN-
creatic Disease ReseArch Consortium (PANDoRA). PANDoRA has
been described in detail elsewhere.38 It is a multicentric study con-
sisting of 11 European countries (Greece, Italy, Germany, Netherland,
Denmark, Czech Republic, Hungary, Poland, Ukraine, Lithuania and
What's new?
Long non-coding RNAs (lncRNAs) are thought to contribute
to cancer development. Here, the authors searched for new
lncRNA variants that are associated with risk of pancreatic
ductal adenocarcinoma (PDAC). From analysis of 15,000
individuals, they obtained 67 variants associated with PDAC
risk. Some of these were located in genes previously associ-
ated with PDAC, an outcome which not only validates the
method but could shed light on the functional relevance of
these genes. The strongest association was to a variant in
the lnc-SMC2-1 gene, and the risk allele is predicted to dis-
rupt cell cycle regulation.
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United Kingdom), Brazil and Japan. PDAC cases were defined by an
established diagnosis of PDAC and controls were individuals of the
general population without a pancreatic disease at recruitment, indi-
viduals that were hospitalized for nontumor-related causes, or blood
donors. For each subject, information on sex, age (age at diagnosis for
cases and age at recruitment for controls) and country of origin was
collected. The PANDoRA study protocol was approved by the Ethics
Commission of the Medical Faculty of the University of Heidelberg. In
accordance with the Declaration of Helsinki, written informed consent
was obtained from each participant. A description of the populations
used is shown in Table 1.
2.2 | Identification of lncRNA and lncSNPs
To obtain the list of all known human lncRNAs, the publicly available
database NONCODE (http://www.noncode.org) was used. The data-
base uses a Coding Noncoding Index algorithm to discriminate
between ncRNA and protein-coding RNA through the coding poten-
tial of each transcript.39 The database uses a unique nomenclature for
the lncRNA, described in detail by Xie et al.40 The NONCODE data-
base was consulted on March 22, 2019 and the list consisted of
11 857 human lncRNAs. To identify all the lncSNPs in each of the
sequences identified through NONCODE, we used LncRNASNP2
(http://bioinfo.life.hust.edu.cn/lncRNASNP#!/), a database of func-
tional SNPs and mutations in human and mouse lncRNAs, obtaining a
list of 10 205 295 lncSNPs.41
2.3 | Sample preparation and genotyping
DNA of PANDoRA cases and controls was extracted from whole blood,
using the QIamp 96 DNA QIAcube HT Kit (Qiagen, Hilden, Germany).
Genotyping was done using TaqMan technology (ThermoFisher Applied
Biosystems, Waltham, Massachusetts) in 384-well plates according to
manufacturer's recommendations. In each plate, an approximately equal
number of cases and controls were used, and duplicate samples (8%)
and no template controls were added for QC purposes. Genotyping
calls were made using QuantStudio 5 Real-Time PCR system
(Thermofisher) and QuantStudio software.
2.4 | Data filtering and statistical analysis
Out of the 10 205 295 lncSNPs identified through LncRNASNP2,
9 787 663 had MAF < 0.01 and were then discarded. Out of the
remaining 417 632 lncSNPs, 121 555 were not present in the
imputed PanScan + PanC4 data sets. The final list of variants
used in the analysis consisted of 296 077 lncSNPs. The logistic
analysis was carried out with PLINK 2.0 (www.cog-genomics.org/
plink/2.0/).
The five resulting independent SNPs with the lowest P values of
association with PDAC risk were then genotyped in a population con-
sisting of 2686 PDAC patients and 2907 controls from PANDoRA.
We observed no deviation from Hardy-Weinberg equilibrium in any
of the genotyped SNPs. The average call rate was 98%. This replica-
tion analysis was adjusted for sex, age and country of origin.
In addition, a gene-based analysis was performed through the
MAGMA v1.08 software to test the association between all long non-
coding genes and PDAC risk.42
Finally, a fixed effect meta-analysis between the results of the
two phases was conducted in the 19 862 individuals included in the
two study phases using R software package (https://cran.r-project.
org/web/packages/rmeta). The Bonferroni-corrected threshold for
statistical significance was 0.05/296077 = 1.69 × 10−7.
2.5 | Bioinformatic tools
We used several databases to link the SNPs with the best associa-
tions with a potential functional explanation. To identify the possible
effect of the SNPs on gene expression, we used the data available in
the Genotype-Tissue Expression (GTEx) project (https://www.
gtexportal.org). We used LncRNASNP2, miRbase (http://www.
mirbase.org) (release 22) and miRDB 6.0 tool (http://mirdb.org) to
identify potential interactions between lncRNAs and miRNAs to
assess the potential effect on gene expression. We used HaploReg
(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php)
and RegulomedB (https://www.regulomedb.org) to test the regula-
tory potential (ie, possible change in transcription factors affinity,
regulation of chromatin state). Finally, we used LDlink (https://
ldlink.nci.nih.gov) to explore the linkage disequilibrium (LD) between
the variants we have identified and polymorphisms reported in the
literature. We have also analyzed the regions nearby the significant
SNPs to look for regulatory regions using the ensemble website
(https://www.ensembl.org/).
TABLE 1 Description of the study population
PanScan PanC4 PANDoRA Total
Diagnosis
Controls 3320 3742 2907 9893
PDAC cases 3274 3933 2686 9969
Total 6594 7675 5593 19 862
Median age (Q1-Q3)
Controls 65 (55-75) 65 (55-75) 59 (47-67) 65 (55-75)
PDAC cases 65 (65-75) 65 (55-75) 66 (58-73) 65 (55-75)
Sex
Female 52% 57% 45% 52%
Male 48% 43% 55% 48%
Note: The age values in the PanScan and PanC4 data sets obtained from
dbGaP were reported in 10-year categories. We used the value of 35 for
the age of all subjects belonging to the 30 to 39 category. Likewise, for
the other age categories we used 45, 55, 65, 75, and 85 years.
Abbreviations: PANDoRA, PANcreatic Disease ReseArch Consortium;
PDAC, pancreatic ductal adenocarcinoma.
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3 | RESULTS
This study was performed using a two-phase approach, a discovery
phase consisting of data on 7207 cases and 7062 controls from four
GWAS conducted on PDAC risk (PanScan I, PanScan II and PanC4),
and a validation phase, in which we performed de novo genotyping of
the most significant SNPs, comprising 2686 PDAC patients and 2907
controls from the PANcreatic Disease ReseArch (PANDoRA) consor-
tium. A description of the populations studied is shown in Table 1.
We used the NONCODE and the LncRNASNP2 databases to estab-
lish a comprehensive list of 296 077 lncSNPs. By testing their associa-
tions in the first phase, we observed 8893 lncSNPs with a statistically
significant association with PDAC risk considering a threshold of
P < .05 (P values ranging from 5.06 × 10−19 to .049). We applied a fil-
ter of P < 1 × 10−4 in order to maximize the chances of reaching
genome-wide significance in the combined PanScan + PanC4 + PAN-
DoRA data set and observed 67 SNPs below that threshold
(Table S2). We then pruned for residual LD among the lncSNPs and
between the lncSNPs and variants already reported in the literature to
be associated with risk of developing PDAC. Details of the associa-
tions with established and putative loci, as well as localizations of
SNPs in lncRNAs and predictions of impact on lncRNA-miRNA bind-
ing, are reported in Table S3. We obtained five candidates
(rs6931760, rs6489786, rs7046076, rs7663891, rs73335863) that
were associated with PDAC risk with a P < 1 × 10−4, had MAF > 0.05
and were independent from known risk loci. Figure 1 shows a scheme
of the selection/elimination process of the lncSNPs and Figure S1
shows regional plots for all the loci in the PanScan + PanC4 data set.
The gene-based analysis using MAGMA revealed that 3108 long non-
coding genes were associated to PDAC risk (P < .05) and 11 consider-
ing a Bonferroni-corrected threshold (0.05/11857 = 4.22 × 10−6). The
top six genes overlap or have SNPs in LD with known PDAC risk loci.
Our five candidates SNPs map to genes that have a range of P values
(multitest of MAGMA) from 6.06 × 10−7 to 3.25 × 10−4. In particular,
the NONHSAG053086.2 gene, where rs7046076 maps, showed an
association with a very strong statistical significance P = 6.06 × 10−7.
The results for all the genes showing statistically significant associa-
tions are listed in Table S4.
In the replication phase, the five SNPs were tested in the PAN-
DoRA population. We observed that the C allele of rs7046076 was
associated with an increase in PDAC risk in the additive model
(ORadd = 1.14, 95% CI = 1.04-1.24, P = .004) and in the codominant
model (OR[C/C vs T/T] = 1.33, 95% CI = 1.09-1.62, P = .005).
The results were meta-analyzed with the data from the discovery
phase and we found a genome-wide significant risk associated with
the C allele of the rs7046076 SNP (ORadd = 1.13, 95% CI = 1.09-1.18,
P = 9.73 × 10−9). Table 2 shows the results of the discovery phase, of
the validation phase and of the meta-analysis for the five SNPs that
were genotyped in PANDoRA. Figure 2 shows the meta-analysis for
rs7046076. In addition, we have also checked the results of the five
SNPs in a pancreatic cancer GWAS conducted in the Japanese popu-
lation and we observed that rs7663891 showed an association with
the risk of developing the disease, with the estimate that goes in the
same direction of our replication phase (OR = 1.08, 95% CI = 1.07-
1.09 and P = .0499)14 but not of the discovery phase.
We investigated the functional potential of rs7046076 with all
the tools described in the methods section. GTEx and Haploreg
showed that rs7046076 is a multitissue eQTL, with no statistically signifi-
cant association in the pancreatic tissue. According to the LncRNASNP2
website, rs7046076 lies in the NONHSAG053086.2 lncRNA that binds to
the hsa-mir-1256, which according to miRDB regulates 381 genes. The C
allele of rs7046076 disrupts the binding between NONHSAG053086.2
and hsa-mir-1256, with ΔΔG = −17.46 kCal/mol (predicted by
LncRNASNP2). LDlink showed that rs4742902, that is in LD with
rs7046076 (r2 = 0.83 in the European populations of 1000 Genomes),
has a RegulomeBD rank of 2b and a score of 0.84, indicating that the
SNP probably binds to a transcription factor and is situated in a region
sensible to DNases. Using Ensembl, we found that nearby the five SNPs
there are several regulatory regions (Table S5).
4 | DISCUSSION
In the last decade, GWAS have been an invaluable tool to identify
thousands of susceptibility loci in many human complex traits; how-
ever, they suffer from two inherent problems: (a) the majority of the
identified SNPs are situated in noncoding region that make their func-
tional interpretation difficult, and (b) considering the stringent statisti-
cal threshold imposed by multiple comparisons (usually P < 5 × 10−8),
only the top results are usually reported, possibly leaving out a large
number of false negatives. To overcome these limitations, in our study
we combined GWAS and functional data in order to identify novel
variants involved in PDAC susceptibility. We focused on lncRNAs
because they are an emergent biomarker in a plethora of human
diseases.
LncRNA deregulation plays a key role in different human cancers,
including PDAC.26,27,43,44 The molecular mechanisms through which
lncRNA could affect cancer development, progression and metastatic
spread are multiple and include regulatory interactions with DNA,
RNA (mRNAs and miRNAs) and proteins (eg, transcription factors and
chromatin modifying complexes).3,27
In the last years, several in vitro studies have shown that deregu-
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invasive and metastatic potential of PDAC cells, as reviewed by
Huang et al.26 In particular, lncRNA-miRNA interactions seem to be of
primary importance in PDAC aggressiveness.26 Recent evidences sug-
gest that functional polymorphisms, regulating lncRNA expression,
could play a decisive role in modulating the risk of developing several
cancer types.29-33,45 With these premises, we investigated the genetic
variability of lncRNAs across the genome in relation to PDAC risk.
We used a two-phase approach and analyzing almost 15 000 indi-
viduals in the discovery phase we identified 67 lncSNPs that were
associated with PDAC risk (P < 1 × 10−4); filtering for residual LD and
possible association with known loci we ended up with a list of five
variants to be tested in a validation phase.
The strongest association we observed, from a statistical point of
view, is the increase in risk of developing PDAC associated with the C
allele of the rs7046076 variant. This SNP was significant in both study
phases and reaches genome-wide significance (P = 9.73 × 10−9) in the
meta-analysis of the two phases. rs7046076 is in the region of SMC2,
a locus previously reported as suggestively associated with PDAC
risk,11 and is in moderate LD (r2 = 0.79, D0 = 1) with rs10991043, the
top SNP reported in that locus. This SNP maps to the NON-
HSAG053086.2 lncRNA (also known as lnc-SMC2-1) that lies on chro-
mosome 9q31.2 (at position 106 786 881, hg38), more than 2.6
megabases away from the well-known ABO-rs505922 locus at 9q34
(r2 = 0 in the populations of European descent of 1000 Genomes).
NONHSAG053086.2 binds to a miRNA (hsa-mir-1256), which is
expressed in several tissues, including pancreatic tissue, and regulates
381 genes. Among the genes with the highest score for binding with
hsa-mir-1256, there are CDKN2B and DAAM1. CDKN2B lies on
9p21.3, a pleiotropic stretch of DNA that includes in addition to
CDKN2B also CDKN2A and CDKN2B-AS1, and has a very complex
genomic context and regulation. There are convincing epidemiologic
and molecular evidences pointing to a key role for the region in cancer
etiology. For example, the CDKN2A gene is frequently mutated in
PDAC,46 while CDKN2B genetic germline variability has been consis-
tently shown by us and others to be associated with risk of PDAC and
pancreatic neuroendocrine tumors.12,47,48 The presence of the
rs7046076 C allele causes the loss of miRNA-lncRNA binding
(as shown in the LncRNASNP2 database), and therefore could be
involved in the deregulation of the genes on 9p21.3 increasing PDAC
risk. In addition, NONHSAG053086.2 regulates DAAM1 (14q23.1)
through the binding with hsa-mir-1256. The protein encoded by this
gene promotes directional vesicular transport and facilitates cell move-
ment. Ang et al have shown that the loss of this protein could lead to
random migration of the cell,49 and a perturbation of DAAM1 regulation
has been reported to facilitate cancer progression and metastasis
through random cell migration.50 Moreover, using the MAGMA soft-
ware, an association with NONHSAG053086.2 gene, where rs7046076
maps, and PDAC risk was highlighted with a p multi of 6.06 × 10−7. All
these evidences confirm that this locus is associated with the PDAC
risk. Using Ensembl, we observed the presence of are several putatively
regulatory regions with variants in LD with the top five SNPs. These
regions seem to have a role in the pancreatic tissues, it is however, diffi-
cult to directly link their effect with the variation determined by the
SNPs. Follow-up studies aimed of uncovering the effect of the polymor-
phisms, especially rs7046076 are therefore warranted.
It is noteworthy that our approach selected a number of SNPs
belonging to loci that were previously reported to be associated with
PDAC risk, either as established loci (ie, significant at genome-wide level)
or as suggestive ones. This implies that (a) our approach is valid because
it successfully identifies known risk loci, and (b) it can shed light to asso-
ciations previously reported but lacking possible functional explanations.
For example, rs9543325 (P = 5.06 × 10−19 in the discovery set),
one of the lncSNPs discarded through LD filtering, maps to the locus
13q22.1, and is the same reported by Petersen et al in 2010 in the
PanScan II GWAS.35 The authors stated that the SNP maps to a
nongenic region between KLF2 and KLF5 without explaining the func-
tion. Conversely herein we have identified that rs9543325 maps to
the gene of lncRNA, NONHSAG067118.1, which gives a possible func-
tional explanation to this finding.
Additional established PDAC risk loci where SNPs identified
with our approach map are NR5A2 (chromosome 1q32.1), ETAA1



























Discovery phase PanScan + PanC4
Validation phase PANDoRA
Overall: Phet=0.863, I²=0.0%
F IGURE 2 Meta-analysis for rs7046076. Discovery phase: PanScan + PanC4; Validation phase: PANDoRA; POP: number of cases + controls;
WGHT: relative weight of the meta-analysis components; P value: association with PDAC risk; Overall Phetand I
2: measures of heterogeneity
between the meta-analysis components. LCI, lower bound of the 95% confidence interval; OR, odds ratio; PDAC, pancreatic ductal
adenocarcinoma; UCI, upper bound of the 95% confidence interval
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(16q23.1). Additionally, one of the SNPs we selected for genotyping
in PANDoRA (rs7663891) is in the region of EDNRA (chromosome
4q31.22), which was reported to be suggestively associated with
PDAC risk,11 although the association is not confirmed in our repli-
cation phase. One quarter of all known PDAC risk loci are linked to
lncRNA function. In addition, gene-based analysis performed with
MAGMA also supported the involvement of lncRNAs in PDAC etiol-
ogy, considering that 3108 out of 11 857 lncRNA genes showed a
statistically significant association with the disease. This clearly
highlights the importance of these molecules in the pathology and
emphasizes the need to further our knowledge on their interaction
with miRNAs and other functional mechanisms.
Obvious strengths of our study are its large size and the rigorous
two-phase approach that contribute to decreasing the possibilities of
spurious findings. In addition, we performed a comprehensive analysis
of the common genetic variability in human lncRNAs, an attempt that
has never been tried before.
A possible limitation is that only individuals of Caucasian descent
were included and therefore we used published data of a GWAS con-
ducted in PDAC, in the Japanese population, to check the association
of our top findings. Only rs7663891 showed a statistically significant
association at the nominal P value level (P = .0499).14 Different find-
ings in genetic association studies conducted in population of differ-
ent ethnicities are frequent and have already been documented in
PDAC susceptibility.16 In addition, the functional explanations that
support our findings are derived from databases and not by direct evi-
dence from experimental results.
In conclusion, we present here a novel PDAC risk locus supported
by a genome-wide statistical significance and a plausible biological
mechanism, pointing to the interplay of lncRNAs and miRNAs in the
maintenance of cellular homeostasis and suggesting that subtle dereg-
ulation of these mechanisms by lncSNPs can lead to cancer. This find-
ing improves our knowledge of genetic factors associated with PDAC
risk and reinforces the role of lncSNPs in the susceptibility to PDAC.
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